GlassScriptPhysician profile
Robb S Friedman
NPI 1669451514
$150,263.30
in general payments reported to CMS, 2019-2025
24 companies · $37K in 2025
The $37K reported for 2025 was more than what 95% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,658 · 2020: $11K · 2021: $20K · 2022: $15K · 2023: $26K · 2024: $36K · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $71K · Travel and Lodging: $15K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,120 · Food and Beverage: $3,978 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $71,022.71 |
| Travel and Lodging | $14,705.37 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,120.00 |
| Food and Beverage | $3,978.33 |
| Education | $123.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $32,357.83 | 2023-2025 | Epkinly |
| Abbvie INC. | $25,212.22 | 2019-2025 | |
| Beigene USA, INC. | $11,452.50 | 2024 | Brukinsa |
| Janssen Biotech, INC. | $11,313.05 | 2021-2025 | Tecvayli, Darzalex, Talvey |
| Adc Therapeutics America, INC. | $10,277.01 | 2022-2025 | |
| Kite Pharma, INC. | $8,919.92 | 2020-2025 | Yescarta |
| Legend Biotech USA INC. | $7,930.00 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $6,750.00 | 2020-2025 | Ninlaro |
| E.R. Squibb & Sons, L.L.C. | $5,837.53 | 2023-2024 | |
| Epizyme, INC. | $4,507.95 | 2020-2021 | |
| Genzyme Corporation | $4,201.93 | 2020-2022 | |
| Beone Medicines USA, INC. | $3,765.09 | 2025 | Brukinsa |
| Novartis Pharmaceuticals Corporation | $3,608.75 | 2024-2025 | |
| Acrotech Biopharma INC. | $3,460.41 | 2025 | Beleodaq |
| Ipsen Biopharmaceuticals, INC | $3,450.00 | 2023 | Tazverik |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $2,184.34 | 2025 | |
| Pfizer INC. | $2,100.00 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $1,692.90 | 2023 | Imbruvica, Epkinly |
| Celgene Corporation | $797.87 | 2023 | |
| Karyopharm Therapeutics INC. | $189.80 | 2023-2025 | Xpovio |
| Gilead Sciences, INC. | $150.00 | 2025 | |
| Sobi, INC | $43.71 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $43.25 | 2025 | Enhertu |
| Stemline Therapeutics INC. | $17.24 | 2023 | Orserdu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robb Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.